This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AQXP Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP) Get AQXP alerts:Sign Up Key Stats Today's Range$20.96▼$22.0750-Day Range$3.68▼$4.0352-Week Range$2.00▼$3.84Volume89,409 shsAverage Volume239,362 shsMarket Capitalization$508.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Read More Receive AQXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquinox Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AQXP Stock News HeadlinesMirum Pharmaceuticals, Inc. (MIRM)February 11, 2024 | finance.yahoo.comWhy Aquinox Pharma (AQXP) Stock Might be a Great PickSeptember 24, 2023 | finance.yahoo.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 22 at 1:00 AM | Behind the Markets (Ad)Aquinox Pharmaceuticals (AQXP) Stock Jumping in After-Hours Trading Following Earnings BeatJuly 26, 2023 | thestreet.comAquinox Pharma's lead product candidate flunks mid-stage trial in COPD; shares plummet 70%June 9, 2022 | seekingalpha.comSee More Headlines AQXP Stock Analysis - Frequently Asked Questions How were Aquinox Pharmaceuticals' earnings last quarter? Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) posted its quarterly earnings results on Thursday, November, 8th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.43. What other stocks do shareholders of Aquinox Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Cos (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), XOMA Royalty (XOMA), Alnylam Pharmaceuticals (ALNY) and NVIDIA (NVDA). Company Calendar Last Earnings11/08/2018Today5/22/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AQXP CIK1404644 Webwww.aqxpharma.com Phone604-629-9223FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.13% Return on Assets-28.08% Debt Debt-to-Equity RatioN/A Current Ratio63.17 Quick Ratio63.17 Sales & Book Value Annual Sales$25 million Price / Sales20.35 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book6.99Miscellaneous Outstanding Shares23,540,000Free FloatN/AMarket Cap$508.70 million OptionableNot Optionable Beta-7.37 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AQXP) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersI wouldn't assume your portfolio is safeJC Parets, CMT and Founder of TrendLabs, warns that a 'Chaos Cycle' is forming in the market - one where damag...Trend Labs | SponsoredSneak Peek: Wall Street’s Little Black BookTom Busby, pro trader and CEO of the Diversified Trading Institute, spent years building a collection of what ...DTI Trader | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
